One-Product Profits Are Real. So Is the Calendar That Ends Them.

Concentration is the model

Read this quarter's results side by side and a pattern emerges that few of the companies advertise: the industry's best growth is concentrated. Madrigal booked $431.3 million of Rezdiffra net sales, up 50% year over year, and reported its first profitable quarter. Harmony's WAKIX delivered $269 million and the company reiterated full-year guidance of $1.0 billion to $1.04 billion. Krystal's VYJUVEK brought in $127.3 million, taking it past $1.1 billion since launch. At ANI, Purified Cortrophin Gel contributed $138.7 million of $290.8 million in total net revenues, growing 36.1%. Corcept's Korlym and its authorized generic produced $249.1 million of a $340.5 million quarter.

None of this is a criticism. Focus produces execution. Madrigal reports more than 55,850 patients on therapy and a market it says is growing. Krystal says VYJUVEK is funding its pipeline. These are well-run commercial engines.

The risk is a date, not a surprise

The view of CompePharma is that these companies should be judged less on this quarter's growth than on how seriously they treat the date when single-product economics change. Harmony is the clearest case, because it says so openly. It points to a multi-layered IP strategy across active legal proceedings and expresses confidence in WAKIX exclusivity to March 2030. That is a useful disclosure, and it also shows that the company's own planning horizon is set by a legal calendar. Its response is a pipeline built around that date: a pitolisant GR application with an April 1, 2027 PDUFA date, a pitolisant HD Phase 3 readout in 2027, and an orexin agonist, BP-205, heading into Phase 2. The company is also changing CEOs on January 1, 2027, so the handover will land in the middle of that sequence.

Other companies show the same structure in different forms. Madrigal is adding a new outcomes trial in cirrhosis, with MAESTRO-NASH OUTCOMES data expected in late 2027. Corcept is pairing a profitable legacy line with Lifyorli, which brought in $91.4 million, and with BELLA Part A data in ovarian cancer. ANI has announced an offer for Egetis Therapeutics to widen its Rare Disease business. In each case, a strong core is being used to build something that does not yet carry the weight.

The strongest counter-argument

The best objection is that diversification is no safer than focus. BioMarin is this season's test case. Its revenue rose 32% to $1.025 billion, helped by a more diversified portfolio after the Amicus acquisition. Yet it also updated full-year guidance to reflect order timing uncertainty and two acquired IPR&D charges. Breadth brought its own volatility, and the bill for buying it showed up in the guidance. Single-asset companies, by contrast, offer investors and partners a clear thesis, and they are executing it.

That is fair, and we do not argue that every company should rush into a second product line. Diversification bought at the wrong price or with a lumpy order book can leave a company worse off. But the objection answers a different question. The issue is not whether concentration is wrong today. It is whether leadership has said, in operational terms, what happens as the calendar closes in.

Treat concentration as a managed position

Strong quarters invite complacency about the next one. The companies in this set have a good case for their present results, and they should be equally clear about the stress case. The ones that fund their second act while the first act is still growing will have choices. The ones that wait until the first act slows will be buying under pressure.

Leaders of single-franchise companies should say plainly how much of the business rests on one product, what the exclusivity or competitive horizon is, and which milestones would show the next layer is ready to carry weight. Boards should tie incentives to those milestones, not only to the current franchise's growth. That is the discipline this season's results ask for.

— The Editors, CompePharma